证券代码：300642 证券简称：透景生命 公告编号：2025-030 上海透景生命科技股份有限公司 关于第四届董事会第十次会议决议的公告 1、上海透景生命科技股份有限公司（以下简称"公司"）第四届董事会第 十次会议（以下简称"本次会议"）通知于 2025 年 04 月 15 日通过邮件或专人 送达的方式通知公司全体董事。 2、本次会议于 2025 年 04 月 25 日在上海市浦东新区汇庆路 412 号公司会议 室以现场结合通讯会议的方式召开。 3、本次会议应出席董事 7 名，实际参加会议的董事 7 名，其中独立董事 3 名，董事俞张富先生以通讯方式参会。 4、本次会议由公司董事长姚见儿先生召集并主持。公司监事及高级管理人 员列席了本次会议。 5、本次会议的通知、召开符合《中华人民共和国公司法》、《中华人民共 和国证券法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上海透景生命科 技股份有限公司章程》、《上海透景生命科技股份有限公司董事会议事规则》的 有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于公司 2025 年 ...

Financial Performance - The company's revenue for Q1 2025 was ¥74,893,130.45, a decrease of 19.53% compared to ¥93,072,134.17 in the same period last year[4] - Net profit attributable to shareholders was ¥471,691.09, representing a significant increase of 110.51% from a loss of ¥4,487,874.40 in the previous year[4] - Basic and diluted earnings per share improved to ¥0.0029 from a loss of ¥0.0277, marking an increase of 110.47%[4] - The company reported a net loss of CNY 924,238.20 for the quarter, compared to a net loss of CNY 6,039,882.63 in the same quarter last year[22] - Total operating revenue for Q1 2025 was CNY 74,893,130.45, a decrease of 19.5% compared to CNY 93,072,134.17 in the same period last year[21] Cash Flow - The net cash flow from operating activities decreased by 43.73% to ¥16,411,586.68 from ¥29,166,783.93 in the previous year[12] - Cash received from sales of goods and services was CNY 90,762,733.09, down 22.5% from CNY 117,217,781.20 in the previous year[24] - The company's cash flow from operating activities included CNY 7,172,358.43 received from other operating activities, compared to CNY 6,554,075.76 in the previous year[24] - Operating cash inflow totaled $98,014,465.76, a decrease from $123,956,954.51 in the previous period[25] - Net cash flow from operating activities was $16,411,586.68, down from $29,166,783.93[25] Investment Activities - Investment activities generated a net cash flow of ¥65,197,109.34, a significant increase from a negative cash flow of ¥45,294,002.32 in the same period last year, reflecting a 243.94% change[12] - Investment cash inflow increased to $183,479,343.73 from $103,421,362.39, primarily due to cash received from investment recoveries[25] - Net cash flow from investment activities was $65,197,109.34, a significant improvement from a negative $45,294,002.32[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,690,994,722.29, down 3.32% from ¥1,748,986,409.73 at the end of the previous year[4] - Total current assets decreased from 918,716,063.66 yuan to 877,362,845.65 yuan, a decline of approximately 4.6%[18] - Total liabilities decreased to CNY 174,638,902.26 from CNY 230,944,723.47, a reduction of 24.4%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,040[14] - The largest shareholder, Yao Jian'er, holds 20.09% of shares, totaling 32,753,700 shares, with 7,100,000 shares pledged[14] - The second largest shareholder, Lingfei Group Co., Ltd., holds 7.38% of shares, totaling 12,035,800 shares, with 10,180,000 shares pledged[14] Research and Development - The company reported a 36.01% reduction in R&D expenses, totaling ¥11,057,969.71 compared to ¥17,281,879.24 in the previous year[11] - Research and development expenses were CNY 11,057,969.71, a decrease of 36.2% from CNY 17,281,879.24 year-over-year[21] Cash and Equivalents - Cash and cash equivalents increased from 308,738,859.31 yuan to 391,089,370.79 yuan, an increase of approximately 26.7%[18] - The ending balance of cash and cash equivalents stood at $385,908,970.79, compared to $365,101,536.86 at the end of the previous period[25] - The net increase in cash and cash equivalents was $88,350,511.48, contrasting with a decrease of $15,575,692.83 previously[25]

上海透景生命科技股份有限公司 关于公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"）于近 日收到上海市科学技术委员会、上海市财政局、国家税务总局上海市税务局联合 颁发的《高新技术企业证书》： 企业名称：上海透景生命科技股份有限公司 证书编号：GR202431004195 发证时间：2024 年 12 月 26 日 证券代码：300642 证券简称：透景生命 公告编号：2025-028 有效期：三年 本次系公司在原《高新技术企业证书》有效期满后进行的重新认定。根据《中 华人民共和国企业所得税法》及其实施条例、《高新技术企业认定管理办法》等 有关规定，公司自本次高新技术企业证书颁发之日起的连续三个会计年度（即 2024 年至 2026 年）将继续享受国家关于高新技术企业的税收优惠政策，即按 15% 的税率缴纳企业所得税。 根据高新技术企业资格相关公示结果，2024 年度公司企业所得税已减按 15% 计缴，本次公司通过高新技术企业重新认定不会对公司此前已披露的《2024 ...

业绩方面，基金调研公司中，6家公司已经公布了一季报，净利润同比增幅最高的是中际旭创、顺络电 子，净利润增长幅度为56.83%、37.02%。公布一季度业绩预告的共有1家。以净利润增幅中值来看，净 利润增幅最高的是天融信，预计净利润中值为-7000.00万元，同比增幅为21.62%。（数据宝） 4月20日基金调研公司一览 昨日基金共对9家公司进行调研，扎堆调研甘源食品、顺络电子、中际旭创等。 证券时报·数据宝统计，4月20日共9家公司被机构调研，按调研机构类型看，基金参与9家公司的调研活 动，其中，10家以上基金扎堆调研公司共6家。甘源食品最受关注，参与调研的基金达39家；顺络电 子、中际旭创等分别获26家、24家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有3家，创业板公司有6家。所属行业来看，基 金调研的公司共涉及5个行业，所属医药生物行业最多，有3家公司上榜；电子、通信等紧随其后，分别 有2家、2家公司上榜。 从基金调研公司的A股总市值统计，总市值在500亿元以上的共有1家，总市值不足100亿元的有3家，分 别是透景生命、甘源食品、天融信等。 市场表现上，基金调研股中，近5日上涨的有 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300642 证券简称：透景生命 公告编号：2025-025 上海透景生命科技股份有限公司 关于回购注销部分激励对象已获授但尚未解除限售的 限制性股票减资通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 1、债权申报登记地点：上海市浦东新区汇庆路412号证券事务部 2、申报时间：2025年04月19日起45天内（9:00-11:30；13:30-17:00；双休日及法定节假日除外）。以邮 寄方式申报的，申报日以寄出邮戳日为准。 3、联系人：胡春阳 4、联系电话：86-21-50495115 上海透景生命科技股份有限公司（以下简称"公司"）于2025年04月18日召开第四届董事会第九次会议， 审议并通过了《关于注销部分股票期权和回购注销部分限制性股票的议案》。根据公司《2020年股票期 权与限制性股票激励计划（草案）》、《2023年股票期权与限制性股票激励计划（草案）》的规定，公 司将对已授予但不再符合解除限售条件的465,900股限制性股票进行回购注销。具体情况请详见公司于 同期在巨潮 ...

上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2025001 | | □分析师会议 | □特定对象调研 □媒体采访 | | --- | --- | --- | | 投资者关系 活动类别 | □路演活动 | □新闻发布会 □业绩说明会 | | | □现场参观 其他：电话会议  | | | 人员姓名 | 华创证券李婵娟、张良龙、太平洋证券李啸岩、中邮证券蔡明子、岑峻宇、 | | | | 上汽颀臻（上海）资产管理有限公司沈怡雯、青榕资产唐明、中信资管魏巍、 | | | | 长江证券（自营）蔡念恒、金科投资张诚、创金合信管理有限公司张小郭、 | | | 参与单位名称及 | 中金公司资产管理部忻郁松、国海医药年庆功、中信证券陈逸飞、博远基金 | | | （排名不分先后） | 管理有限公司谭飞、东方证券自营部王光宇、上海汐泰投资管理有限公司董 | | | | 函、中航基金管理有限公司方岑、上海理成资产管理有限公司周锐、中广云 | | | | 投资有限责任公司马遥、英大保险资产管理有限公司李海、汇添富基金管理 | | | | 股份有限公司袁建军 | | | 时 间 | 2025 年 04 月 20 日（ ...

Group 1 - The core viewpoint of the news is that TuoJing Life (300642.SZ) has disclosed its annual report for 2024, revealing significant changes in institutional and foreign investment holdings [1] - As of April 19, 2025, a total of 42 institutional investors hold shares in TuoJing Life, with a combined holding of 36.8578 million shares, accounting for 22.61% of the total share capital [1] - The top ten institutional investors collectively hold 22.38% of the shares, which represents a decrease of 5.93 percentage points compared to the previous quarter [1] Group 2 - In terms of public funds, 36 new public funds have been disclosed this period compared to the previous quarter, including several notable funds such as the Medical Device ETF and the West China Quantitative Growth Mixed A [1] - Regarding foreign investment, only one foreign fund, UBS AG, has reduced its holdings, with a decrease of 0.31% [2] - Several foreign institutions, including MERRILL LYNCH INTERNATIONAL and Goldman Sachs, have not disclosed their holdings this period [2]

Core Viewpoint - The company operates in the in vitro diagnostic (IVD) industry, focusing on the development, production, and sales of diagnostic products, particularly in cancer detection and autoimmune diseases, while facing challenges from centralized procurement policies impacting pricing and revenue [1][30]. Company Overview - The company is engaged in the research, production, and sales of in vitro diagnostic products, primarily in the fields of cancer detection, autoimmune diseases, and infectious diseases [2][3]. - The company’s products are widely used in various clinical settings across China, with a significant presence in tertiary hospitals [2][3]. Business Model - The company employs a combined sales model of distribution and direct sales, with a focus on linking instrument sales to reagent sales [20][21]. - The company has established a marketing network covering all 31 provinces in China, utilizing both distributors and direct sales to reach end-users [21][22]. Financial Performance - The company reported a revenue of 436.78 million yuan, a decrease of 19.53% year-on-year, primarily due to a significant drop in reagent sales [33]. - The revenue from HPV products decreased by 31.38% following the implementation of centralized procurement [33]. Research and Development - The company invests approximately 15% of its revenue into R&D, focusing on various diagnostic technologies and expanding its product line [34]. - The company has developed multiple products for cancer screening and has completed clinical studies for new detection methods [34][35]. Industry Overview - The global IVD market is projected to reach $109.2 billion by 2024, with significant growth expected in the immunodiagnostic and molecular diagnostic segments [26]. - The Chinese IVD market is estimated to be around $6.1 billion in 2024, with an annual growth rate of 8.0% anticipated [27]. Regulatory Environment - The company is adapting to the challenges posed by centralized procurement policies, which have led to increased price competition and impacted revenue [30][32]. - The company has successfully registered multiple medical devices and is compliant with international standards, allowing access to various markets [19][34].

Financial Performance - The company's basic earnings per share decreased by 61.13% to 0.2130 yuan in 2024 from 0.5480 yuan in 2023 [1] - Net profit fell by 60.67% to 0.35 billion yuan in 2024 compared to 0.89 billion yuan in 2023 [1] - Operating revenue declined by 19.52% to 4.37 billion yuan in 2024 from 5.43 billion yuan in 2023 [1] - Return on equity dropped by 61.64% to 2.29% in 2024 from 5.97% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 47.4232 million shares, accounting for 34.44% of the circulating shares, a decrease of 6.5804 million shares from the previous period [1] - UBS AG reduced its holdings by 50% to 777.19 thousand shares, representing 5.64% of total share capital [2] - New entrants among the top shareholders include He Jianbiao, Feng Jiaqing, and Niu Zhengxiang, with holdings of 121.91 thousand, 112.49 thousand, and 108.00 thousand shares respectively [2] Dividend Distribution - No specific information on dividend distribution or plans was provided in the documents [3]

上海透景生命科技股份有限公司 内部控制审计报告 二○二四年度 内部控制审计报告 信会师报字[2025]第 ZA11103 号 上海透景生命科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了上海透景生命科技股份有限公司（以下简称透景 生命）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是透景生命董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 中国注册会计师： 中国•上海 二〇二五年四月十八日 内控审计报告 第 2 页 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 四、 财务报告内 ...